OCUGEN, INC. Adjustments to Additional Paid in Capital, Warrant Issued
OCUGEN, INC. (OCGN) reported Adjustments to Additional Paid in Capital, Warrant Issued of $14.20 million for the 1-month period ending 2026-03-31, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-06
- OCUGEN, INC. adjustments to additional paid in capital, warrant issued for fiscal 2015 was $11.00K, a 78.43% decline from fiscal 2014.
- OCUGEN, INC. adjustments to additional paid in capital, warrant issued for fiscal 2014 was $51.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 1 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2026-03-31 | $14.20M 10-Q · filed 2026-08-06 | |
| 2015-12-31 | $11.00K 10-K · filed 2017-03-16 | |
| 2014-12-31 | $51.00K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |